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Abstract
Background Robotic surgery has been in existence for
30 years. This study aimed to evaluate the overall periop-
erative outcomes of robotic surgery compared with open
surgery (OS) and conventional minimally invasive surgery
(MIS) across various surgical procedures.
Methods MEDLINE, EMBASE, PsycINFO, and Clini-
calTrials.gov were searched from 1990 up to October 2013
with no language restriction. Relevant review articles were
hand-searched for remaining studies. Randomised con-
trolled trials (RCTs) and prospective comparative studies
(PROs) on perioperative outcomes, regardless of patient
age and sex, were included. Primary outcomes were blood
loss, blood transfusion rate, operative time, length of hos-
pital stay, and 30-day overall complication rate.
Results We identified 99 relevant articles (108 studies,
14,448 patients). For robotic versus OS, 50 studies (11 RCTs,
39PROs) demonstrated reduction in blood loss [ratio ofmeans
(RoM) 0.505, 95 % confidence interval (CI) 0.408–0.602],
transfusion rate [risk ratio (RR) 0.272, 95 %CI 0.165–0.449],
length of hospital stay (RoM 0.695, 0.615–0.774), and 30-day
overall complication rate (RR0.637, 0.483–0.838) in favour of
robotic surgery. For robotic versusMIS, 58 studies (21 RCTs,
37 PROs) demonstrated reduced blood loss (RoM 0.853,
0.736–0.969) and transfusion rate (RR 0.621, 0.390–0.988) in
favour of robotic surgery but similar length of hospital stay
(RoM 0.982, 0.936–1.027) and 30-day overall complication
rate (RR 0.988, 0.822–1.188). In both comparisons, robotic
surgery prolonged operative time (OS: RoM 1.073,
1.022–1.124; MIS: RoM 1.135, 1.096–1.173). The benefits of
robotic surgery lacked robustness on RCT-sensitivity analy-
ses. However, many studies, including the relatively few
available RCTs, suffered fromhigh risk of bias and inadequate
statistical power.
Conclusions Our results showed that robotic surgery
contributed positively to some perioperative outcomes but
longer operative times remained a shortcoming. Better
quality evidence is needed to guide surgical decision
making regarding the precise clinical targets of this inno-
vation in the next generation of its use.
Keywords Robotic surgery  Conventional surgery 
Perioperative outcomes
Robotic surgery represents a fundamental innovation in
health care that is designed to enhance the quality of care
for patients. Puma 560 was the first surgical robot applied
in a clinical setting to obtain neurosurgical biopsies in 1985
[1]. The authors concluded that the robot contributed to
improved accuracy. Since then, increasingly advanced
surgical robots have been developed to assist in a rapidly
expanding range of operative procedures and anatomical
targets (Fig. 1). The drivers for continuous innovation stem
from the potential to offer greater operative precision that
may translate into enhanced clinical outcomes and the
accompanying background of corporate revenues within
the healthcare technology sector.
To achieve these goals, current robotic platforms are
designed to incorporate advanced features, such as, (i) dex-
terous capability with accompanying instrumentation, (ii)
& Hutan Ashrafian
h.ashrafian@imperial.ac.uk
1 Department of Surgery and Cancer, Imperial College
London, 10th Floor QEQM Building, St. Mary’s Hospital,
London W2 1NY, UK
2 Institute of Global Health Innovation, Imperial College
London, London SW7 2NA, UK
123
Surg Endosc
DOI 10.1007/s00464-016-4752-x
and Other Interventional Techniques 
augmented visualisation, (iii) improved stability, (iv) natural
coordination, (v) accurate cutting capacity, (vi) reliable
execution, and (vii) enhanced surgeon ergonomics. These
features can theoretically increase surgical precision by
rendering difficult operative tasks easier to perform safely.
Moreover, surgical robots have retained the capacity to
enable surgery through smaller incisions. Collectively, these
characteristics aim to enhance outcomes beyond that
achievable through conventional operative methods.
The adoption and diffusion of robotic surgery demonstrate
a positive trend in some geographical areas, particularly for
advanced economies. This can be illustrated by the prominent
application of the daVinci Surgical System (dVSS; Intuitive
Surgical Inc., Mountain View, Sunnyvale, California, USA),
which has US Food and Drug Administration (FDA) clear-
ance across a multitude of specialties [2], demonstrating its
greatest exposure for urological and gynaecological proce-
dures [3]. For example, more than half of radical prostatec-
tomies and about a third of benign hysterectomies are already
performed robotically in the USA [3, 4].
Despite offering some elements of innovative technology,
the necessary evidence to justify the expanding investment
in robotic surgery remains ambiguous. Whilst the concept of
robotic surgery is almost universally favoured, its wide-
spread promotion across all healthcare sectors requires
robust justification, not least because it can be very costly
[5]. Studies comparing outcomes of robotic surgery with
conventional approaches for specific robots and procedures
are certainly not scarce. However, the systematic assessment
of robotic surgery collectively as a single entity has not been
performed. As we approach the end of the third decade
following the pioneering use of the first surgical robot, an
overview of this innovation may be useful for understanding
the adoption of innovations in health care.
The aim of this comprehensive systematic review and
meta-analysis was to draw evidence from comparative
studies in robotic surgery, regardless of specialty and pro-
cedure type, and irrespective of patient age and sex. We
avoided the biases of retrospective studies that dominate the
literature by focussing only on randomised controlled trials
(RCTs) and non-randomised prospective studies. In com-
paring potentially very heterogeneous studies, we empha-
sised a methodology that identified the proportional benefit
of robotic surgical outcomes compared with controls in each
study. This offered internal consistency from each study. We
were then able to calculate a pooled proportional benefit for
specific robotic surgical outcomes for all studies.
In this review, we evaluated core perioperative variables
as our primary outcomes. These were (i) blood loss, (ii)
blood transfusion rate, (iii) operative time, (iv) length of
hospital stay, and (v) 30-day overall complication rate. In
robotic surgical studies, these perioperative variables were
most commonly addressed. Analyses were performed
separately for robotic versus open surgery (OS) and robotic
versus minimally invasive surgery (MIS). As a secondary
outcome, we calculated the proportion of studies that
demonstrated adequate statistical power for the evaluation
of these clinical outcomes.
Fig. 1 Timeline demonstrating
selected events in the history
and development of surgical
robots
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Materials and methods
This review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-analy-
ses (PRISMA) statement [6].
Inclusion and exclusion criteria
We defined surgery as any interventional procedure
involving alteration in anatomy and that either requires a
skin (or mucosal) incision or puncture. Patients requiring
surgery for which a robotic approach was a feasible alter-
native approach to OS or MIS were included. There was no
age or sex restriction. Controls were eligible only if
patients underwent surgery and no robotic assistance was
provided. RCTs and prospective studies that addressed one
or more core perioperative surgical outcomes (blood loss,
blood transfusion rate, operative time, length of hospital
stay, and 30-day overall complication rate) were included.
For operative time, we included studies that explicitly
defined it as starting from skin incision to skin closure (for
intravascular procedures, we used procedure time, which
was generally defined as time from first venous puncture to
sheath withdrawal at the end of the procedure). Whilst this
measure does not represent the total theatre occupation
time, it was selected to improve comparability because
operative time was variedly defined in the literature.
We excluded studies where surgical robots were used for
stereotactic, endoscopic, or single-incision laparoscopic
surgery. Robotic instrument positioners without concurrent
use of other robotic instrumentation tools were also exclu-
ded, as were innovations that are generally not considered
robotic technology, such as remote magnetic catheter navi-
gation and pure computer navigation systems. We also
discounted studies with historical controls that preceded the
robotic arm considerably (that is, greater than a year) as well
as those that retrospectively reviewed and analysed
prospective databases. Laboratory studies involving syn-
thetic models, animals, or cadavers were not considered.
Search methodology
Using the OvidSP search engine, the MEDLINE, EMBASE,
and PsycINFO databases were searched on 2 September
2013 with the terms: robot* (tw) AND [intervention* (tw)
OR surg* (tw)]. The same search terms were used to search
the ClinicalTrials.gov registry to identify potentially relevant
trials. On 26 May 2014, these trials were reviewed to
identify any relevant published data. To avoid losing gen-
erally older papers which had used the term computer-as-
sisted instead of robot, we also performed a search on 7
October 2013 with the terms: [surgery, computer-assisted
(MESH, exp) OR computer-assisted surg* (tw) OR com-
puter-aided surg* (tw)] AND [intervention* (tw) OR surg*
(tw)]. Studies from 1990 to the search dates were included.
There was no language restriction. Relevant review articles,
including health technology assessments, found through our
search strategy were also hand-searched to identify any
remaining studies.
Data collection and analysis
Study selection
Articles were screened from titles and abstracts by three
authors independently (AT, SM, and AS). Potentially rel-
evant articles that appear to fit the inclusion and exclusion
criteria were obtained in full text. These were indepen-
dently assessed for eligibility by the same authors. Articles
were excluded if they had duplicate or incomplete data, or
if they were only available in abstract form. Any dis-
agreement was resolved through discussion with a senior
author (HA).
Dealing with duplicate publications
If several articles reported outcomes from a single study,
the article with the most comprehensive results (most
number of patients and/or most recent publication) was
included. If this article failed to report outcomes that were
otherwise available in the duplicate article, then the addi-
tional data from the duplicate article were included.
Data extraction
One author (AT) extracted data into an Excel 2011 data-
base (Microsoft Corp., Redmond, Washington, USA),
which were then reviewed independently by three authors
(SM, AS, and HA). For each article, the year of publica-
tion, study design, total number of patients, number of
patients in each arm, robot and control type, baseline
characteristics, and results of outcome measures of interest
were extracted. For continuous outcomes, we extracted the
mean and standard deviation (or if unavailable, the median
and standard error, range, or interquartile range). For cat-
egorical outcomes, we recorded the number of events.
Risk of bias assessment
Three authors (AT, SM, and AS) independently assessed the
risk of bias of eligible articles. Quality of articles with more
than one study was assessed on their overall methodology.
The Cochrane risk of bias tool [7] was applied to RCTs.
Seven key domains were assessed: method of random
sequence generation, allocation concealment, blinding of
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participants and personnel, blinding of outcome assessors,
completeness of outcome data, selective reporting, and other
potential sources of bias. Based on a set of listed criteria,
each domain was judged to have either a low, high, or
unclear risk of bias. If a study had unclear or high risk of
bias for one or more key domains, then it was classified as
having, respectively, an unclear or high risk of bias overall.
If instead all the key domains had low bias risk, then the
study was judged to have a low risk of bias overall [7].
For prospective studies, the Newcastle–Ottawa scale
(NOS) [8] was used for quality scoring. The NOS judges
studies on three categories: the selection of the study
groups (comprising four numbered items: representative-
ness of exposed cohort, selection of non-exposed cohort,
ascertainment of exposure, demonstration that outcomes
were not present at start of study), the comparability of the
groups (comprising one numbered item: comparability of
cohorts on basis of study design or analysis), and outcomes
(comprising three numbered items: assessment of outcome,
appropriateness of length of follow-up, adequacy of fol-
low-up of cohorts). From a set of listed criteria, a maxi-
mum of one star can be awarded for each numbered item,
except for comparability where a maximum of two stars
can be awarded. The possible NOS score ranges from 0 to 9
stars. We classified studies with C7 stars as ‘‘higher’’
quality and\7 stars as ‘‘lower’’ quality.
Risk of bias assessment was made at the level of out-
comes. We assessed perioperative outcomes together as a
class [7, 9]. If a study addressed several perioperative
outcomes, the risk of bias for a particular domain was
judged based on the outcome that was most affected by the
study methodology. Any disagreement with risk of bias
assessment was resolved through discussion with a senior
author (HA).
Data synthesis and statistical methods
Meta-analysis was based on control type, that is, either
robotic versus OS or robotic versus MIS. Wherever possible,
we used results from intention-to-treat analyses. Continuous
outcomes were analysed by calculating the ratio of means
(RoM) for each study, with expression of uncertainty of each
result represented by the 95 % confidence intervals (CI)
[10]. We substituted median for mean in studies where only
the median was reported. When the calculated RoM was 1,
computation was not possible. Consequently, these results
were excluded. Categorical outcomes were analysed using
risk ratio (RR) with 95 % CI [7]. Studies reporting cate-
gorical outcomes with no events in both the robotic and
control groups were excluded, as their effect sizes were not
computable. We performed meta-analysis if two or more
separate studies were available. The inverse-variance, ran-
dom-effects model of DerSimonian and Laird [11] was used
for both continuous and categorical outcomes. This was
accomplished using Stata 13 (StataCorp., College Station,
Texas, USA). Sensitivity analysis on RCTs was also per-
formed. The I2 statistic was used to estimate the degree of
heterogeneity between studies, where larger values indicate
increasing heterogeneity [12].
Post hoc power analysis (significant at the 5 % level,
two-tailed t test) was conducted for all eligible studies
using the G*Power 3.1 programme [13]. Power was cal-
culated for large (d = 0.8), medium (d = 0.5), and small
(d = 0.2) effect sizes. We defined adequate statistical
power as[80 %. We also identified studies with clearly
specified primary outcomes and where power analysis was
performed to determine the required sample size for ade-
quate assessment of these outcomes.
Results
Search results
A total of 43,132 articles were identified from the databases.
This included 104 trials from the ClinicalTrials.gov registry,
of which one [14] was subsequently found to contain relevant
published data. After removing duplicates, 28,574 articles
were screened based on their titles and abstracts. Of these,
1702 potentially relevant full-text articles were retrieved for
further evaluation. We found 97 articles that met the inclu-
sion criteria. Two additional articles were identified through
hand-searching. In total, 99 articles, involving 14,448
patients overall, were included in this review (Fig. 2).
Description of included studies
Of the included articles, all but one [15] investigated out-
comes in adult patients. Overall, there were 31 and 68
articles, respectively, that were based on RCT and non-
randomised prospective comparative designs. They
encompassed a wide range of specialties and procedures
(Tables 1, 2). Some articles comprised more than one
comparison or study [16–23].
Robotic versus OS
For robotic versus OS, there were 50 studies (11 RCTs and
39 prospective studies) (Table 1). The year of publication
ranged from 1998 to 2013. In total, there were 5910 and 4237
patients in the robotic and OS groups, respectively. The
smallest and largest sample sizes were 14 and 1738,
respectively. The surgical robots used in these studies were
the dVSS, Zeus Robotic Surgical System (ZRSS; Computer
Motion Inc., Santa Barbara, California, USA), ROBODOC
Surgical System (Curexo Technology Corp., Fremont,
Surg Endosc
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California, USA), Acrobot Surgical System (The Acrobot
Co. Ltd., London, UK), CASPAR system (OrtoMaquet,
Rastatt, Germany), and SpineAssist (Mazor Robotics Ltd.,
Caesarea, Israel).
Robotic versus MIS
For robotic versus MIS, there were 58 studies (21 RCTs
and 37 prospective studies), which were published between
2001 and 2014 (Table 2). Taking into account all studies,
the robotic and MIS groups consisted of 1991 and 2310
patients, respectively. Sample sizes ranged from 12 to 390.
The surgical robots used were the dVSS, ZRSS, Mona
(Intuitive Surgical), and Sensei Robotic Catheter System
(Hansen Medical Inc., Mountain View, California, USA).
Risk of bias assessment
All included articles were assessed for the quality of their
methodology. Of note, all 31 RCT articles suffered from a
high risk of bias because they all showed a high risk of bias
in the performance bias domain (Fig. 3). This was primarily
Fig. 2 Flow chart of included
studies. *Some articles
contained more than one
comparison or study (see text).
OS open surgery, MIS
minimally invasive surgery,
RCT randomised controlled trial
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Table 1 Studies comparing robotic versus open surgery
References Procedure Design No. of patients, n Robot Perioperative
outcomes addresseda
Power
Total R C Effect size
Large Medium Small
Bertani et al.
[16]b
Rectal resection PRO 86 52 34 dVSS BL, LOS, C 0.948 0.611 0.146
Kim et al. [68] Rectal resection PRO 200 100 100 dVSS BT, LOS, C 1.000 0.940 0.291
Bertani et al.
[16]b
Colectomy PRO 79 34 45 dVSS BL, LOS, C 0.935 0.584 0.140
Lee et al. [47] Thyroidectomy PRO 84 41 43 dVSS BL, OT, LOS, C 0.952 0.619 0.148
Kim et al. [48] Thyroidectomy PRO 37 19 18 dVSS BL 0.657 0.315 0.091
Ryu et al. [96] Thyroidectomy PRO 90 45 45 dVSS LOS, C 0.964 0.738 0.180
Menon et al. [34] Prostatectomy PRO 60 30 30 dVSS BL, BT, OT, LOS, C 0.861 0.478 0.119
Tewari et al. [36] Prostatectomy PRO 300 200 100 dVSS BL, BT, OT, LOS, C 1.000 0.983 0.370
Farnham et al.
[31]
Prostatectomy PRO 279 176 103 dVSS BL, BT 1.000 0.980 0.362
Wood et al. [35] Prostatectomy PRO 206 117 89 dVSS BL, BT, LOS, C 1.000 0.943 0.293
Nelson et al. [95] Prostatectomy PRO 1003 629 374 dVSS LOS, C 1.000 1.000 0.864
Ham et al. [37] Prostatectomy PRO 298 188 110 dVSS BL, LOS, C 1.000 0.986 0.383
Ficarra et al. [32] Prostatectomy PRO 208 103 105 dVSS BL, BT, LOS, C 1.000 0.948 0.300
Carlsson et al.
[111]
Prostatectomy PRO 1738 1253 485 dVSS C 1.000 1.000 0.962
Hong et al. [38] Prostatectomy PRO 51 26 25 dVSS BL, BT 0.799 0.417 0.108
Doumerc et al.
[69]
Prostatectomy PRO 714 212 502 dVSS BT, LOS, C 1.000 1.000 0.684
Kordan et al. [33] Prostatectomy PRO 1244 830 414 dVSS BL, BT 1.000 1.000 0.913
Di Pierro et al.
[70]
Prostatectomy PRO 150 75 75 dVSS BT, C 0.998 0.860 0.229
Kim et al. [112] Prostatectomy PRO 763 528 235 dVSS C 1.000 1.000 0.721
Ludovico et al.
[39]
Prostatectomy PRO 130 82 48 dVSS BL, LOS, C 0.992 0.780 0.194
Rhee et al. [42] Cystectomy PRO 30 7 23 dVSS BL, BT, OT, LOS 0.432 0.201 0.073
Nix et al. [25] Cystectomy RCT 41 21 20 dVSS BL, LOS, C 0.704 0.345 0.096
Ng et al. [41] Cystectomy PRO 187 83 104 dVSS BL, OT, LOS, Cc 1.000 0.922 0.272
Martin et al. [40] Cystectomy PRO 33 19 14 dVSS BL, LOS 0.595 0.280 0.085
Khan et al. [17]b Cystectomy PRO 100 48 52 dVSS BL, BT, OT, LOS, C 0.977 0.696 0.167
Parekh et al. [26] Cystectomy RCT 40 20 20 dVSS BL, BT, OT, LOS, C 0.693 0.338 0.095
Masson-Lecomte
et al. [49]
Nephrectomy PRO 100 42 58 dVSS BL, BT, OT, LOS, C 0.974 0.686 0.165
Parekattil et al.
[23]b
Vasovasostomy PRO 94 66 28 dVSS OT 0.939 0.592 0.142
Parekattil et al.
[23]b
Vasoepididymostomy PRO 61 44 17 dVSS OT 0.787 0.406 0.106
Bucerius et al.
[18]b
CABG PRO 117 24 93 dVSS LOS 0.934 0.581 0.139
Kiaii et al. [94] CABG PRO 100 50 50 ZRSS LOS, C 0.977 0.697 0.168
Poston et al. [43] CABG PRO 200 100 100 dVSS BL, LOS, C 1.000 0.940 0.291
Bachinsky et al.
[71]
CABG PRO 52 25 27 dVSS BT, LOS 0.807 0.424 0.109
Balduyck et al.
[110]
Anterior mediastinal
mass resection
PRO 36 14 22 dVSS C 0.623 0.295 0.088
Hoekstra et al.
[20]b
Endometrial cancer
staging
PRO 58 32 26 dVSS BL, OT, LOS, C 0.846 0.461 0.116
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due to the lack of surgeon blinding, which is unlikely to be
possible in clinical trials of robotic surgery. As periopera-
tive outcomes are especially vulnerable to performance
bias, this risk was judged to be high. The subject of patient
blinding, which is difficult in surgical trials but potentially
feasible [24], was frequently unaddressed or unreported by
authors. Most RCTs showed low risk of attrition bias, with
complete perioperative outcome data. In many trials, how-
ever, the risk of bias related to sequence generation, allo-
cation concealment, blinding of outcome assessor, and
selective reporting was unclear, as sufficient information
was not available due to poor reporting.
Of 68 articles of non-randomised prospective design, 55
(80.9 %) were of ‘‘higher’’ quality (Tables 3, 4). All
prospective studies met the criteria for ascertainment of
exposure, absence of outcome at the start of study, outcome
assessment, and duration of follow-up. Most prospective
studies also selected their control cohort from the same
community as the robotic cohort and showed adequate fol-
low-up. Many of them suffered from poor comparability, as
expected from the lack of randomisation where selection
bias is a caveat. In some cases, the representativeness of the
robotic cohort in the community was felt not be adequate.
Meta-analyses of perioperative surgical outcomes
(i) Blood loss
Robotic versus OS
There were six RCT [25–30] and 23 prospective [16, 17,
20, 31–49] studies reporting on blood loss, giving a total of
29 studies overall. Meta-analysis demonstrated blood loss
Table 1 continued
References Procedure Design No. of patients, n Robot Perioperative
outcomes addresseda
Power
Total R C Effect size
Large Medium Small
Go¨c¸men et al.
[45]
Endometrial cancer
staging
PRO 22 10 12 dVSS BL, BT, OT, LOS, C 0.428 0.199 0.073
Jung et al. [19]b Endometrial cancer
staging
PRO 84 28 56 dVSS BT, OT, LOS, C 0.927 0.569 0.137
Lowe et al. [46] Hysterectomy—
cervical cancer
PRO 14 7 7 dVSS BL, OT, LOS, C 0.281 0.139 0.064
Collins et al. [44] Sacrocolpopexy PRO 48 30 18 dVSS BL 0.748 0.375 0.101
Bargar et al. [28] Total hip arthroplasty RCT 136 70 66 ROBODOC BL, LOS, C 0.996 0.825 0.212
Bach et al. [109] Total hip arthroplasty PRO 50 25 25 ROBODOC C 0.791 0.410 0.107
Honl et al. [76] Total hip arthroplasty RCT 141 61 80 ROBODOC OT, C 0.997 0.832 0.215
Siebel et al. [113] Total hip arthroplasty PRO 71 36 35 CASPAR C 0.914 0.547 0.132
Nishihara et al.
[27]
Total hip arthroplasty RCT 156 78 78 ROBODOC BL, BT 0.999 0.873 0.237
Nakamura et al.
[107]
Total hip arthroplasty RCT 146 75 71 ROBODOC C 0.998 0.851 0.224
Cobb et al. [106] Unicompartmental
knee arthroplasty
RCT 28 13 15 Acrobot C 0.529 0.246 0.080
Park et al. [108] Total knee arthroplasty RCT 62 32 30 ROBODOC C 0.872 0.490 0.121
Song et al. [29] Total knee arthroplasty RCT 60 30 30 ROBODOC BL, C 0.861 0.478 0.119
Song et al. [30] Total knee arthroplasty RCT 100 50 50 ROBODOC BL, C 0.977 0.697 0.168
Ringel et al. [77] Spinal pedicle screw
insertion
RCT 60 30 30 SpineAssist OT, LOS 0.861 0.478 0.119
Total 10,147 5910 4237
BL blood loss, BT blood transfusion rate, OT skin-to-skin operative (or procedure) time, LOS length of hospital stay, C 30-day overall
complication rate, CABG coronary artery bypass grafting, RCT randomised controlled trial, PRO non-randomised prospective comparative
studies
a Relevant to this review
b More than one comparison or study in an article
c Not computable, as there were more complications than the number of patients in the open group—complication data were excluded from
meta-analysis as a result; for robotic studies on hips and knees, n = number of limbs
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Table 2 Studies comparing robotic versus minimally invasive surgery
References Procedure Design No. of patients, n Robot Perioperative
outcomes addresseda
Power
Total R C Effect size
Large Medium Small
Pigazzi et al. [56] Rectal resection PRO 12 6 6 dVSS BL, LOS, C 0.241 0.123 0.061
Patriti et al. [55] Rectal resection PRO 66 29 37 dVSS BL, BT, LOS, C 0.888 0.510 0.125
Baik et al. [89] Rectal resection PRO 113 56 57 dVSS OT, LOS, C 0.984 0.726 0.176
Kim et al. [75] Rectal resection PRO 209 62 147 dVSS BT, OT, LOS, C 1.000 0.908 0.260
Bertani et al. [16]b Colectomy PRO 64 34 30 dVSS BL, LOS, C 0.882 0.502 0.123
Park et al. [51] Colectomy RCT 70 35 35 dVSS BL, BT, LOS, C 0.910 0.541 0.131
Jime´nez Rodrı´guez et al. [74] Colorectal
resection
RCT 56 28 28 dVSS BT, LOS, C 0.836 0.451 0.114
Heemskerk et al. [102] Rectopexy PRO 33 14 19 dVSS LOS 0.595 0.280 0.085
Wong et al. [57] Rectopexy PRO 63 23 40 dVSS BL, LOS, C 0.853 0.468 0.117
Cadie`re et al. [97] Fundoplication RCT 21 10 11 Mona LOS, C 0.412 0.193 0.072
Melvin et al. [84] Fundoplication PRO 40 20 20 dVSS OT, C 0.693 0.338 0.095
Draaisma et al. [50] Fundoplication RCT 50 25 25 dVSS BL, OT, LOS, C 0.791 0.410 0.107
Morino et al. [78] Fundoplication RCT 50 25 25 dVSS OT, LOS, C 0.791 0.410 0.107
Nakadi et al. [99] Fundoplication RCT 20 9 11 dVSS LOS, C 0.392 0.184 0.071
Lehnert et al. [15] Fundoplication PRO 20 10 10 dVSS OT, C 0.395 0.185 0.071
Mu¨ller-Stitch et al. [98] Fundoplication RCT 40 20 20 dVSS LOS, C 0.693 0.338 0.095
Hartmann et al. [101] Fundoplication PRO 80 18 62 dVSS LOS, C 0.839 0.454 0.114
Sanchez et al. [100] RYGB RCT 50 25 25 dVSS LOS, C 0.791 0.410 0.107
Benizri et al. [85] RYGB PRO 200 100 100 dVSS OT, LOS, C 1.000 0.940 0.291
Mu¨hlmann et al. [104] Various bariatricc PRO 20 10 10 dVSS LOS, C 0.395 0.185 0.071
Park et al. [91] Gastrectomy PRO 150 30 120 dVSS OT, LOS, C 0.973 0.682 0.164
Ruurda et al. [79] Cholecystectomy RCT 20 10 10 dVSS OT 0.395 0.185 0.071
Nio et al. [105] Cholecystectomy PRO 20 10 10 ZRSS LOS, C 0.395 0.185 0.071
Zhou et al. [52] Cholecystectomy RCT 40 20 20 ZRSS BL, LOS, C 0.693 0.338 0.095
Kornprat et al. [90] Cholecystectomy PRO 46 20 26 ZRSS OT 0.749 0.376 0.101
Berber et al. [58] Liver resection PRO 32 9 23 dVSS BL, OT, C 0.504 0.234 0.078
Brunaud et al. [93] Adrenalectomy PRO 28 14 14 dVSS OT, LOS, C 0.531 0.247 0.080
Morino et al. [81] Adrenalectomy RCT 20 10 10 dVSS OT, LOS, C 0.395 0.185 0.071
Wu et al. [66] Adrenalectomy PRO 12 5 7 ZRSS BL, LOS, C 0.236 0.121 0.061
Ploussard et al. [59] Prostatectomy PRO 288 83 205 dVSS BL, BT, LOS, C 1.000 0.969 0.335
Gosseine et al. [67] Prostatectomy PRO 247 122 125 dVSS BL, BT, LOS, C 1.000 0.975 0.347
Asimakopoulos et al. [72] Prostatectomy RCT 112 52 60 dVSS BT, C 0.987 0.744 0.182
Porpiglia et al. [53] Prostatectomy RCT 120 60 60 dVSS BL, OT, LOS, C 0.991 0.775 0.192
Khan et al. [17]b Cystectomy PRO 106 48 58 dVSS BL, BT, OT, LOS, C 0.982 0.719 0.174
Caruso et al. [63] Nephrectomy PRO 20 10 10 dVSS BL, BT, LOS, C 0.395 0.185 0.071
Hemal et al. [60] Nephrectomy PRO 30 15 15 dVSS BL, BT, LOS, C 0.562 0.262 0.083
Kural et al. [62] Nephrectomy PRO 31 11 20 dVSS BL, BT, LOS, C 0.540 0.251 0.081
Masson-Lecomte et al. [61] Nephrectomy PRO 265 220 45 dVSS BL, BT, LOS, C 0.998 0.861 0.230
Bucerius et al. [18]b CABG PRO 97 24 73 dVSS LOS 0.920 0.557 0.134
Mierdl et al. [92] CABG PRO 46 30 16 dVSS OT, C 0.715 0.352 0.097
Sarlos et al. [54] Hysterectomy—
benign disease
RCT 95 47 48 dVSS BL, OT, LOS, C 0.971 0.674 0.162
Paraiso et al. [73] Hysterectomy—
benign disease
RCT 52 26 26 dVSS BT, OT 0.807 0.424 0.109
Hoekstra et al. [20]b Endometrial cancer
staging
PRO 39 32 7 dVSS BL, OT, LOS, C 0.463 0.215 0.075
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in the robotic arm to be 50.5 % of that in the OS arm
(Fig. 4). This reduction was significant (95 % CI
0.408–0.602). There was high heterogeneity in the results
(I2 = 98.0 %). Sensitivity analysis on RCTs showed
reduction in blood loss, but this was no longer significant
(pooled RoM: 0.807, 95 % CI 0.563–1.051, I2 = 96.3 %).
Robotic versus MIS
Twenty-two studies reported blood loss as an outcome
measure. Of these, six were RCT studies [14, 50–54] and
16 were prospective studies [16, 17, 20, 55–67]. Meta-
analysis of these studies confirmed a significant reduction
in blood loss in favour of robotic surgery, which was
85.3 % of that experienced by patients in the MIS arm
(95 % CI 0.736–0.969) (Fig. 4). The heterogeneity was
high (I2 = 98.2 %). Sensitivity analysis performed on
RCTs and, however, revealed a non-robust result (pooled
RoM: 0.830, 95 % CI 0.653–1.008, I2 = 95.9 %).
(ii) Blood transfusion rate
Robotic versus OS
Blood transfusion rate was investigated in two RCT [26,
27] and 16 prospective [17, 19, 31–36, 38, 42, 45, 49, 68–
71] studies. Forty-two of 2127 patients (2.0 %) in the
robotic group needed blood transfusion compared with 249
Table 2 continued
References Procedure Design No. of patients, n Robot Perioperative
outcomes addresseda
Power
Total R C Effect size
Large Medium Small
Jung et al. [19]b Endometrial cancer
staging
PRO 53 28 25 dVSS BT, OT, LOS, C 0.814 0.430 0.110
Paraiso et al. [80] Sacrocolpopexy RCT 68 35 33 dVSS OT, LOS, C 0.901 0.528 0.128
Seror et al. [64] Sacrocolpopexy PRO 67 20 47 dVSS BL, LOS, C 0.839 0.454 0.114
Anger et al. [14] Sacrocolpopexy RCT 78 40 38 dVSS BL, C 0.937 0.587 0.141
El Hachem et al. [65] Various
gynaecological—
unspecified
PRO 91 39 52 dVSS BL, LOS, C 0.962 0.646 0.154
Kolvenbach et al. [103] AAA repair PRO 39 8 31 ZRSS LOS 0.502 0.233 0.078
Malcolme-Lawes et al. [21]b AF ablation—robot
30 s
RCT 20 10 10 Sensei BT, OT, C 0.395 0.185 0.071
Malcolme-Lawes et al. [21]b AF ablation—robot
60 s
RCTd 20 10 10 Sensei BT, OT, C 0.395 0.185 0.071
Steven et al. [83] AF ablation RCT 50 25 25 Sensei OT, C 0.791 0.410 0.107
Kautzner et al. [87] AF ablation PRO 38 22 16 Sensei OT, C 0.659 0.316 0.091
Di Biase et al. [86] AF ablation PRO 390 193 197 Sensei OT, C 1.000 0.998 0.504
Steven et al. [82] AF ablation RCT 60 30 30 Sensei OT 0.861 0.478 0.119
Tilz et al. [22]b AF ablation—robot
30W
PRO 29 4 25 Sensei OT 0.299 0.146 0.065
Tilz et al. [22]b AF ablation—robot
20W
PRO 35 10 25 Sensei OT 0.546 0.254 0.081
Rillig et al. [88] AF ablation PRO 70 50 20 Sensei OT 0.846 0.461 0.116
Total 4301 1991 2310
BL blood loss, BT blood transfusion rate, OT skin-to-skin operative (or procedure) time, LOS length of hospital stay, C 30-d overall complication
rate, RYGB Roux-en-Y gastric bypass, CABG coronary artery bypass grafting, AAA abdominal aortic aneurysm, AF atrial fibrillation/flutter, RCT
randomised controlled trial, PRO non-randomised prospective comparative study
a Relevant to this review
b More than one comparison or study in an article
c Gastric banding, implantable gastric stimulator, band revision
d Quasi-RCT (10 patients who underwent robotic AF ablation of 60-s duration were not randomized compared with 10 control patients that were
randomised); for Baik 2009, n = 57 (control) for C and n = 51 (control) for OT and LOS, as 6 converted cases were excluded from analysis by
authors; for Sarlos 2012, n = 47 (robotic) and n = 48 (control) for analysis of C, as no operations were performed in 5 patients, and for BL, OT,
and LOS, n = 50 in each arm, as missing values were replaced with median of available measurements in respective study arm; for Mierdl 2005,
n = 30 (robotic) for analysis of C but n = 24 for OT, as data not shown for 6 patients
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of 1869 patients (13.3 %) in the open group. One study
[27] was excluded from quantitative synthesis, as its effect
size was not computable. Meta-analysis of the remaining
17 studies demonstrated the risk of blood transfusion with
robotic surgery to be 27.2 % of that of OS. This reduction
in favour of robotic surgery was significant (95 % CI
0.165–0.449). The results showed moderate heterogeneity
(I2 = 55.2 %). Sensitivity analysis on RCTs was not done,
as only one study was available. In this RCT, no significant
difference in blood transfusion requirement was demon-
strated (RR 0.800, 95 % CI 0.400–1.600) [26].
Robotic versus MIS
Six RCT [21, 51, 72–74] and ten prospective [17, 55, 59–
63, 67, 75] studies reported blood transfusion requirement.
Taking all these studies together, 4.2 % (33/789) of
patients who underwent robotic intervention compared
with 6.5 % (56/856) of MIS patients received blood
transfusion. Computation of valid RR was not possible in
three studies [21, 51, 63], hence their exclusion from meta-
analysis. From the remaining 13 studies, we demonstrated
a significant reduction in the requirement for blood trans-
fusion in patients who underwent robotic surgery compared
with MIS (pooled RR 0.621, 95 % CI 0.390–0.988). The
heterogeneity was low (I2 = 0.0 %). Nevertheless, the
result of sensitivity analysis on RCTs was inconsistent
(pooled RR 1.329, 95 % CI 0.325–5.438, I2 = 0.0 %).
(iii) Operative time (skin-to-skin)
Robotic versus OS
Sixteen studies assessed operative time. These comprised
three RCT [26, 76, 77] and 13 prospective [17, 19, 20, 23,
34, 36, 41, 42, 45–47, 49] studies. Meta-analysis showed
robotic surgery to increase operative time by 7.3 %, which
was significant (95 % CI 1.022–1.124). High heterogeneity
was found (I2 = 91.8 %). Sensitivity analysis on RCTs
showed a consistent result (pooled RoM: 1.162, 95 % CI
1.016–1.308, I2 = 86.8 %).
Robotic versus MIS
Operative time was investigated by 12 RCT [21, 50, 53, 54,
73, 78–83] and 18 prospective [15, 17, 19, 20, 22, 58, 75,
84–93] studies. There was a significant prolongation of
operative time by 13.5 % over MIS when surgical robots
were utilised (95 % CI 1.096–1.173). Heterogeneity was
high (I2 = 92.3 %). When only RCTs were considered in a
sensitivity analysis, the result remained robust (pooled
RoM: 1.202, 95 % CI 1.119–1.286, I2 = 87.1 %).
(iv) Length of hospital stay
Robotic versus OS
Thirty studies compared length of hospital stay between
robotic and open interventions. There were 4 RCT [25, 26,
28, 77] and 26 prospective [16–20, 32, 34–37, 39–43, 45–
Fig. 3 Risk of bias graphs of
randomised controlled trials
comparing robotic versus open
surgery (above) and robotic
versus minimally invasive
surgery (below)
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47, 49, 68, 69, 71, 94–96] studies. The result for one study
[26] was not computable. Meta-analysis of the remaining
29 studies revealed length of stay for patients who under-
went robotic surgery to be 69.5 % of those who underwent
OS. This decrease was significant (95 % CI 0.615–0.774).
Heterogeneity was high (I2 = 98.5 %). In contrast, when
only RCTs were considered, the improvement in length of
stay was lost (pooled RoM: 1.038, 95 % CI 0.878–1.197,
I2 = 89.4 %).
Robotic versus MIS
Length of hospital stay was addressed by 40 studies, of
which 13 were RCT [50–54, 74, 78, 80, 81, 97–100] and
were prospective [16–20, 55–57, 59–66, 75, 85, 89, 91, 101–
105] studies. Ten studies [16, 20, 50, 52, 57, 91, 97, 100,
104, 105] were excluded from meta-analysis, as their effect
sizes were not computable. Meta-analysis of the remaining
30 studies showed no significant difference in duration of
stay (pooled RoM: 0.982, 95 % CI 0.936–1.027). High
heterogeneity was noted (I2 = 93.4 %). Sensitivity analysis
on RCTs remained robust (pooled RoM: 1.001, 95 % CI
0.955–1.047, I2 = 80.2 %).
(v) Overall complication rate (30 day)
Robotic versus OS
Overall complications were compared in nine RCT [25, 26,
28–30, 76, 106–108] and 28 prospective [16, 17, 19, 20, 32,
34–37, 39, 41, 43, 45–47, 49, 68–70, 94–96, 109–113]
studies. From these studies, the overall complication rate
was 11.6 % (515/4453) in the robotic arm compared with
21.4 % (693/3245) in the open arm. Results from three
studies [29, 96, 109] did not allow for computable RRs.
From the remaining 34 studies, meta-analysis demonstrated
a significant decrease in overall complication rate in favour
of robotic surgery, which was 63.7 % of that with OS
(95 % CI 0.483–0.838). High heterogeneity was present
(I2 = 81.9 %). Sensitivity analysis on RCTs was, however,
inconsistent with the primary analysis (pooled RR 1.090,
95 % CI 0.631–1.881, I2 = 59.9 %).
Robotic versus MIS
Forty-eight studies investigated complications. There were
18 RCT [14, 21, 50–54, 72, 74, 78, 80, 81, 83, 97–100] and
30 prospective [15–17, 19, 20, 55–66, 75, 84–87, 89, 91,
92, 101, 104, 105] studies. Taking all these studies into
consideration, the overall complication rate in the robotic
arm was 16.1 % (288/1789) compared with 15.7 % (317/
2025) in the MIS arm. Valid effect sizes in the form of RR
were not producible from results of nine studies [15, 52, 66,T
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78, 83, 84, 87, 104, 105]. Meta-analysis involving the
remaining 39 studies demonstrated no significant differ-
ence in overall complication rate between robotic and MIS
(pooled RR 0.988, 95 % CI 0.822–1.188). Heterogeneity
was low (I2 = 23.0 %). When sensitivity analysis was
performed on RCTs, the result remained robust (pooled
RR 1.187, 95 % CI 0.851–1.654, I2 = 15.4 %).
Results of our meta-analyses are summarised in Fig. 5.
Post hoc power analyses
With respect to RCT studies, for large effect sizes, just 17
[14, 27–30, 51, 53, 54, 72–74, 76, 77, 80, 82, 107, 108] of
32 studies (53.1 %) had adequate statistical power (that is,
power[80 %). This fell to four studies [27, 28, 76, 107]
(12.5 %) for medium effect sizes. For small effect sizes,
no RCT study had adequate power.
Analysis of the 76 prospective studies revealed that just
47 [16–20, 23, 31–37, 39, 41, 43, 47, 49, 55, 57, 59, 61, 64,
65, 67–71, 75, 85, 86, 88, 89, 91, 94–96, 101, 111–113] of
them (61.8 %) had adequate power for outcome evalua-
tion, assuming large effect sizes. For medium effect sizes,
20 studies [31–33, 35–37, 41, 43, 59, 61, 67–70, 75, 85,
86, 95, 111, 112] (263 %) were sufficiently powered.
Only three studies [33, 95, 111] (4.2 %) had adequate
power for small effect sizes.
The lack of statistical power in many studies is not sur-
prising given that in only 16 RCT (50 %) and six prospective
(7.9 %) studies were primary outcomes clearly defined and a
priori power analysis performed (Table 5). Furthermore,
only a handful of these studies [51, 54, 73, 80, 82, 85] were
powered to the outcomes investigated in this review.
Results of post hoc power analyses for individual
studies are presented in Tables 1 and 2.
Discussion
The term ‘‘disruptive innovation’’ represents a process
where a product establishes itself at the bottom of a market
and climbs through this sector to displace competitors
[114]. Initial characteristics of a disruptive innovation
model include: (i) simpler products and services, (ii)
smaller target markets, and (iii) lower gross margins. As a
result, these innovations can ‘‘create space’’ at the bottom
of the market to allow new disruptive competitors to
emerge. Currently in the field of robotic surgery, the
promise of simplicity has yet to be translated into daily
practice. Furthermore, the evidence regarding cost efficacyT
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and gross margins has been poorly documented so that
decisions regarding the adoption of robotic surgery remain
controversial.
However, to disregard robotic surgery completely as an
unfulfilled promised in its 30 years of existence may be
imbalanced. Our meta-analyses of all RCTs and prospective
studies to date, regardless of specialty and procedure type,
revealed a decrease in blood loss and blood transfusion rate
with robotic surgery when compared with both OS and MIS.
Additionally, comparison against OS demonstrated a reduc-
tion in length of hospital stay and overall complication rate in
favour of robotic surgery.
The ability of robotic surgery to reduce blood loss and
need for blood transfusion may be attributed to its
advanced features, which could improve surgical precision.
This would be important in avoiding injury to vessels and
other structures that can cause unintended bleeding. The
additional benefits of robotic surgery over OS, in the form
of shorter length of hospital stay and fewer complications,
may partly be due to its capacity for minimal access. These
benefits have been demonstrated in conventional minimally
invasive surgical procedures [115–118], where the positive
effect of reduced tissue trauma has been implicated [118].
Given its added features, the inability of robotic surgery to
achieve improved length of stay and complication rate over
MIS can be considered surprising. This may be reflective of
the status that surgical robots have not yet exceeded their
effects beyond those of conventional minimally invasive
platforms for these outcomes. Alternatively, these out-
comes may be inadequate markers for accurately capturing
the increased precision of robotic surgery. More sensitive
assessment tools of precision are advocated in future trials,
which might include video appraisal of intraoperative tis-
sue handling, errors, and efficiency [52, 105].
When RCTs were analysed separately, the proportional
benefits of robotic surgery were lost. Given their higher level
of evidence, these RCTs may be considered as more rep-
resentative of the true population effect, although they are
limited by a profound lack of numbers. We identified only
31 clinical RCTs on robotic surgery, which is a fraction
(0.1 %) of the 28,574 potentially relevant articles. Many
RCTs failed to clearly define primary outcomes and perform
a priori power analysis, which led to inadequate sample sizes
and hence, statistical power necessary for outcome evalua-
tion. Through post hoc analyses, we showed that just over
half of all RCTs were adequately powered to detect a true
difference in outcomes for large effect sizes. For smaller
effect sizes, this deficiency, inevitably, was further ampli-
fied. These findings are probably related to common barriers
in undertaking successful surgical RCTs, including ethical
issues, challenging patient recruitment and randomisation
due partly to lack of equipoise, learning curve, inexperience
in designing trials, inadequate medical statistical knowledge,
problematic long-term follow-up, and insufficient funding
and resources [24, 119]. Furthermore, difficulty in blinding
is a major methodological barrier [120, 121]. Consequently,
all included RCTs were considered to suffer from a high risk
of performance bias, and accordingly, a high risk of bias
overall [7]. Together, these factors could explain the non-
robust results.
The demonstration of longer operative time with robotic
surgery contradicts its proposed aims of facilitating oper-
ative tasks that would otherwise be difficult to perform
efficiently with conventional tools. One possible explana-
tion is the requirement for additional steps in their
deployment. For example, docking is needed for surgical
robots such as the dVSS [73, 80]. Hardware issues could
also explain the longer operative time, as surgical robotic
Fig. 5 Pooled proportional
change in perioperative
outcomes for robotic versus
open surgery and robotic versus
minimally invasive surgery,
with 95 % confidence interval.
RoM ratio of means, RR risk
ratio, OS open surgery, MIS
minimally invasive surgery.
*Significant effect
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instruments may be cumbersome to place or switch effi-
ciently, or may be insufficiently adapted for the specific
purpose [78, 80, 81, 97].
The surgical learning curve has implications on our
findings. Before study commencement, individual surgeons
have typically performed far fewer robotic cases than con-
ventional ones [51, 53, 54, 72, 73, 107]. This disparity could
disadvantage robotic surgery due to relatively less famil-
iarity. This could further explain the prolonged operative
time of robotic surgery. Nevertheless, our demonstration of
at least equivalent outcomes for other perioperative variables
may be regarded as a favourable effect of robotic surgery.
By allowing achievement of similar or better outcomes
despite the relative lack of user experience, surgical robots
may be important in facilitating training and attainment of
competences. Furthermore, many surgeons may view sur-
gical robots as an ‘‘enabling technology’’, without which it
would not be possible for them to perform certain complex
minimally invasive procedures [122]. Pure laparoscopic
radical prostatectomy, which demonstrates significant tech-
nical challenges, is an example of a procedure where robotic
assistance in suturing and other laparoscopic tasks is
important [123]. Although robotic surgery needs to
demonstrate more than just equivalent patient outcomes to
be cost-effective due to its substantial costs, its potential
positive effects on surgeon ability must also be considered.
This systematic review has some limitations. Our focus
on blood loss, blood transfusion rate, operative time, length
of hospital stay, and complications was based primarily on
the fact that these were the most commonly reported
Table 5 Studies with clearly defined primary outcomes and where power analysis was undertaken a priori
Study Procedure Design Primary outcome
OT LOS C Onc Func Cost Other
Robot versus MIS
Draaisma et al. [50] Fundoplication RCT 4 Barium swallow,
manometry, ph study
Morino et al. [78] Fundoplication RCT 4
Steven et al. [83] AF ablation RCT 4 Radiofrequency duration
Steven et al. [82] AF ablation RCT 4
Asimakopoulos et al.
[72]
Prostatectomy RCT 4
Paraiso et al. [80] Sacrocolpopexy RCT 4
Park et al. [51] Colectomy RCT 4
Sarlos et al. [54] Hysterectomy—benign disease RCT 4
Porpiglia et al. [53] Prostatectomy RCT 4
Paraiso et al. [73] Hysterectomy—benign disease RCT 4
Benizri et al. [85] Roux-en-Y gastric bypass PRO 4
El Hachem et al. [65] Various gynae—unspecified PRO 4 Pain
Anger et al. [14] Sacrocolpopexy RCT 4
Robot versus OS
Cobb et al. [106] Unicompartmental knee
arthroplasty
RCT 4 Leg alignment
Wood et al. [35] Prostatectomy PRO 4 Quality of life
Nix et al. [25] Cystectomy RCT 4
Hong et al. [38] Prostatectomy PRO 4 Venous gas embolism
Song et al. [29] Total knee arthroplasty RCT 4 Leg alignment
Ringel et al. [77] Spinal pedicle screw insertion RCT 4 Implant position
Collins et al. [44] Sacrocolpopexy PRO 4 Return to baseline activity
(accelerometer)
Song et al. [30] Total knee arthroplasty RCT 4 Leg alignment
Kim et al. [48] Thyroidectomy PRO 4 Intraocular pressure
Note absence of outcome for blood loss and blood transfusion
OT operative time (includes fluoroscopy time), LOS length of stay, C complication, Onc oncological (includes lymph node yield), Func
functional (includes erectile function, continence), RYGB Roux-en-Y gastric bypass, AF atrial flutter/fibrillation, RCT randomised controlled
trial, PRO non-randomised prospective comparative study
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outcomes in the robotic surgery literature. However, these
standard parameters may not fully demonstrate the true
value of robotic surgery, especially when the overall ben-
efits are not always clearly perceptible in the short term.
Utilisation of dedicated research parameters should be
encouraged [124]. Already, there is an increasing inclina-
tion towards such parameters that are probably more rele-
vant, including functional, oncological, and quality of life
outcomes, specific anatomical–pathological endpoints
(such as nerve damage control), and ergonomics. With
continuing improvement in outcome parameter selection
by clinical research teams, future evidence synthesis cen-
tred on these parameters may better reflect the added value
of robotic surgery.
Our appraisal of robotic surgery through an exclusively
clinical viewpoint has also meant that other elements of
innovation evaluation could not be incorporated into our
conclusions. These include the impact of surgical robotics
on intellectual property and patent generation, resource
management, healthcare leadership, mentorship, training,
cost efficacy, marketing strategy, business strategy, and
stakeholder value generation.
When meta-analyses were possible, the heterogeneity
was frequently high. However, this is not unexpected given
the wide variability in patient cohorts and interventions.
There was additional variability within specific procedures.
For instance, Nissen [50, 78, 84, 97–99], Toupet [84], Dor
[101], and Thal [15] fundoplications were variant tech-
niques performed in different studies. Furthermore, the
extent of robotic assistance varied from its utilisation in
anastomotic suturing only [103] to totally robotic proce-
dures [21, 22, 82, 83, 85–88, 92, 100]. Methodological
diversity in the form of different study designs and risks of
bias also contributed to the heterogeneity.
We incorporated different surgical robots in our review,
including those that are no longer in use, such as the ZRSS.
However, our intention was not to compare outcomes of
specific procedures obtainable through currently available
robots but to evaluate, via an overview of commonly
addressed perioperative outcomes, whether the goals of
robotic surgery in general have been achieved. Hence, we
offered a unique perspective on robotic surgery by cover-
ing the 30 years of its existence. Accordingly, we also
elected not to stratify our analysis based on robot or pro-
cedure type. Consequently, this restricts the applicability of
this review, so that the individual stakeholder interested in
outcomes for a specific intervention may not be able to
draw sufficiently relevant evidence from our results.
Prospective studies were included to address the paucity
of RCTs. Although practical, their inclusion inevitably
introduces other biases associated with this study design.
Moreover, caution is advised in the interpretation of
complication data, as there were inconsistencies in their
reporting. Many authors failed to comply with the quality
criteria [125] for complication reporting. There was also a
lack of agreement in terms of what constitutes complica-
tions, such as with regard to blood transfusion and con-
version. Nevertheless, this issue is not unique to our
included studies [126, 127]. Additionally, studies on
robotic surgery continue to suffer from several method-
ological flaws, including a lack of studies that offer mul-
tiple endpoint analysis [128] in such a complex field.
The Society of American Gastrointestinal and Endo-
scopic Surgeons [122] and European Association of Endo-
scopic Surgeons [124] consensus statements on robotic
surgery have also highlighted the lack of high-quality data in
evaluating the health outcomes of this technology. Upcom-
ing research efforts should improve on current method-
ological deficiencies. The implementation of outcome
registries for robotic surgery is important to document and
compare benefits and harms and in identifying the direction
for future development [122]. More robust controlled trials
should be undertaken, particularly in areas where robotic
surgery has shown some potential, such as complex hepa-
tobiliary surgery, bariatric and upper gastrointestinal revi-
sional surgery, gastric and oesophageal cancer surgery,
rectal surgery, and surgery for large adrenal masses [124].
Conclusions
After the promising pioneering clinical application of PUMA
560 in 1985, the stage was set for robotic surgery to assume
the role of a significant disruptive innovation in health care.
Three decades on, our analysis across a wide range of sur-
gical robots identified their overall positive contribution in
reducing blood loss and blood transfusion rate over OS and
MIS. Additionally, against OS, they showed overall pro-
portional improvement in length of hospital stay and overall
complication rate. These beneficial effects were lost when
only RCTs were appraised, although these RCTs were
themselves limited. Longer operative time was a common
caveat. Further well-conducted surgical trials are needed to
confirm these findings. Whilst the barriers for these trials
may seem insurmountable, solutions to overcoming them are
now increasingly recognised. These may involve ensuring
protocol transparency, improving trial dissemination, creat-
ing specialised trial units, establishing dedicated outcome
monitoring groups, implementing appropriate minimum
surgeon experience to reduce the impact of learning curves,
and incorporating research training in the surgical curriculum
[119]. To ensure better outcomes for future robotic surgery, a
multidisciplinary approach during product development
involving close collaboration between surgeons and engi-
neers, in addition to inclusive patient engagement, is
mandatory. With the advent of more affordable, enriching
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technologies can be modularly incorporated into conven-
tional surgical approaches such as intraoperative fluores-
cence imaging, high-definition 3-D visualisation, wristed
endoscopic hand tools, and navigation systems, robotic sur-
gery risks degenerating into an unfulfilled promise if it fails
to innovate in line with stakeholders’ needs.
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